Expert committee recommends new Novo Nordisk growth hormone for EU approval
Novo Nordisk has broken ground for marketing growth hormone somapacitan in the EU after EMA expert panel CHMP adopts positive opinion of the treatment.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
Just under five months after Novo Nordisk secured a US Food and Drug Administration (FDA) approval for sending the once-weekly growth hormone Sogroya on the market the European Medicines Agency (EMA) also announces their positive assessment of the treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
